| Exclusion Criteria: | 1) Prior exposure to any chimeric antibody
2) Any evidence of clinically significant bleeding defined as gross hematuria, hemoptysis, or gastrointestinal bleeding
3) Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand Disease or Hemophilia)
4) Any history of thromboembolic events (e.g., DVT or PE) including central venous catheter-related thrombosis within the past 12 months
5) Any evidence or history of hypercoagulable state (e.g., shortened aPTT)
6) Concurrent therapy with oral or parenteral anticoagulants with exception of low dose anticoagulants to maintain patency of indwelling lines or ports
7) Concurrent hormone therapy (e.g., estrogen contraceptives, hormone replacement, anti-estrogen)
8) Chemotherapy, immunotherapy or radiotherapy within 4 weeks of day 0 (6 weeks for nitrosoureas and mitomycin C) or patients who have not recovered from treatment-related side effects due to agents administered more than 4 weeks earlier (stable, nonhematological residual toxicities of Grade 1 or less and Grade 2 dry skin or alopecia are allowed)
9) Investigational therapy within 4 weeks of day 0
10) Evidence of CNS metastatic disease at prestudy (normal MRI of the brain required); patients with a known history of CNS metastatic disease that were effectively treated and have a normal MRI at prestudy are eligible
11) Major surgery within 4 weeks of day 0
12) Pregnant or nursing women
13) All patients of reproductive potential must agree to use an approved form of barrier contraception.
14) Uncontrolled intercurrent disease (e.g. diabetes, hypertension, thyroid disease)
15) Any history of angina pectoris, coronary artery disease or cerebrovascular accident, or transient ischemic attack.
16) A history of any condition requiring anti-platelet therapy with the exception of general cardiovascular prophylaxis with aspirin.
17) Any history of any condition requiring treatment (past or current) with coumarin-type agents within past 12 months
18) Cardiac arrhythmia requiring medical therapy.
19) Serious non-healing wound (including wound healing by secondary intention, ulcer, or bone fracture).
20) Requirement for chronic daily treatment with NSAIDs, anti-platelet drugs (e.g. phosphodiesterase inhibitors, adenosine diphosphate receptor antagonists) or steriods.
21) Known chronic infection with HIV or hepatitis.
22) Washout periods of concurrent medication to be observed: NSAIDs 1 week; Steriods 4 weeks; Aspirin 3 weeks; Anticoagulants (e.g. prophylactic heparin or enoxaparin) 3 weeks; Hormones (estrogenic compounds; anti-estrogens progesterone compounds) 6 weeks |